Bendamustine is an alkylating medication used for the treatment of patients with CLL (Chronic lymphocytic leukemia), and Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of the treatment with rituximab or a rituximab containing regimen.
The recommended dose for CLL is bendamustine 100 mg/m2, which should be administered intravenously (IV) over 30-minutes on the Days 1’st and 2’nd of a 28 day cycle, up to the 6-cycles.
The recommended dose for NHL is 120mg/m2, which should be administered intravenously over 60 minutes on Days 1’st and 2’nd of a 21 day cycle, up to the 8 cycles.
Is Bendamustin FDA approved drug?
FDA approved this drug in 2008 for the treatment of Chronic lymphocytic leukemia and many more.
What are all the ingredients of medicine along with Bendamustine?
Bendamustine hydrochloride is the active ingredient, and the inactive ingredient is mannitol.
From which class of drug does Bendamustine belong?
Bendamustine specifically belongs to the class of drugs named alkylating agents.
What are commonly reported side effects of bendamustine?
Fever, low blood cell counts, nausea, diarrhea, loss of appetite, cough, and rash
The Indian Generic Medicines is a Consultancy and Service company providing access to genuine generic medicines to patients all across the world. We also have own pharmacy named as Indian Generic Medicines which work under compliant distribution guidelines.
© 2023 Indian Generic Medicines. All rights reserved.
